At 50, Robin McCoy diagnosed with retinitis pigmentosa (RP), a genetic mutation leading to vision loss. By 2019, she became legally blind and began utilizing a cane for mobility. In search of potential treatments, McCoy applied for clinical trials, eventually connecting with neuroscientist Sheila Nirenberg from Weill Cornell Medicine. Nirenberg's early-stage trial focusing on optogenetic therapy seeks to restore vision by introducing light-sensing proteins into surviving retinal cells. In February 2024, McCoy received an injection in hopes of improving her visual field.
I really didn't care; I just wanted to not go completely blind.
The aim is to overcome the loss or dysfunction of the eye's light-reactive cells.
Collection
[
|
...
]